Ustekinumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.

**Synonyms:** - CNTO 1275 - CNTO1275 - Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer - Stelara - USTEKINUMAB